about
Immune modulation during latent herpesvirus infectionReview of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project dataVaccine-mediated immunity against dengue and the potential for long-term protection against diseaseWanted, dead or alive: New viral vaccinesVaricella zoster vaccines and their implications for development of HSV vaccinesImmunization of hematopoietic stem cell transplant recipients against vaccine-preventable diseases.Vaccination to prevent varicella: Goldman and King's response to Myers' interpretation of Varicella Active Surveillance Project dataVaricella vaccination in Europe - taking the practical approach.Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015An outbreak of varicella among schoolchildren in Taipei.Primary versus secondary failure after varicella vaccination: implications for interval between 2 dosesHow advances in immunology provide insight into improving vaccine efficacy.Determinants of varicella breakthrough: results of a 2012 case control study.A systematic approach for the identification of novel, serologically reactive recombinant Varicella-Zoster Virus (VZV) antigensSuccesses and challenges in varicella vaccineVaricella-zoster virus pneumonia in an adult population: has mortality decreased?Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries.Effectiveness of 2 doses of varicella vaccine in children.Impact of 2-dose vaccination on varicella epidemiology: Connecticut--2005-2008Herpes Zoster Risk Reduction through Exposure to Chickenpox Patients: A Systematic Multidisciplinary ReviewVaricella zoster virus latency.Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responsesSeroepidemiology of varicella-zoster virus in Korean adolescents and adults using fluorescent antibody to membrane antigen test.Epidemiological game-theory dynamics of chickenpox vaccination in the USA and Israel.NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: persistent immune deficiency in pediatric transplant survivorsFailure of a Single Varicella Vaccination to Protect Children With Cancer From Life-Threatening Breakthrough Varicella.Novel genetic variation identified at fixed loci in ORF62 of the Oka varicella vaccine and in a case of vaccine-associated herpes zosterHuman papillomavirus, vaccines and women's health: questions and cautions.Should the UK introduce varicella vaccine?Single-dose varicella vaccine effectiveness in school settings in China.A varicella outbreak in a school with high one-dose vaccination coverage, Beijing, China.Two-dose varicella vaccine effectiveness and rash severity in outbreaks of varicella among public school studentsThe HPV vaccine: an analysis of the FUTURE II study.Seroepidemiology of varicella-zoster virus in Korea.Asthma and risk of breakthrough varicella infection in children.Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT)Zoster vaccine live for the prevention of shingles in the elderly patient.Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease.Varicella outbreak in the patients during group therapy: seroprevalence in a healthcare system during breakthrough varicella occurrence.An Evaluation of Voluntary Varicella Vaccination Coverage in Zhejiang Province, East China.
P2860
Q24624044-F881AFEC-EF6B-4545-BCEA-B1036A433107Q26863614-28806A9F-DCFE-4BEB-98ED-E263682DC4E8Q27014663-AFE2CC12-1628-4240-8328-2872B26DF7CBQ27489979-7277F3D3-2653-4637-8528-5E26DBC5FC4CQ28280820-C7FFDFBD-B290-415F-A226-F436D0FB64E4Q30401036-80365D07-24DC-4837-B9EA-F8B881314E26Q30701352-727F3E04-F77F-42EE-A0FF-5A1C2DAAAEF6Q33454919-1B7CF19D-A3A1-4ACA-8859-738D51FB3055Q33698107-238171BB-2209-4258-8FBE-2F5FE15F7242Q33870506-42D1F8F0-AE5B-462F-AD7D-019E8F0373F9Q33880341-DA310A5D-5AE0-4404-B129-DC6F10473220Q33896995-7CB0CC76-80DF-4023-A72E-D8E37E1294B4Q34033922-9B1B23AB-097E-4DB9-A4AD-8FADA5A85B66Q34043787-872BAAFF-51E2-4D17-9140-0212F4E15C4FQ34416710-DC501EFF-3D55-4F97-9228-3E4BCA466C51Q34615489-8A56CDB2-3779-443F-8864-D07085773DC3Q34683751-60FF0EEC-82E6-43C9-9F52-30CA23B160CAQ34763888-9E64E3AF-7CB4-4919-BC91-6488C0A319F9Q34764434-617E5B31-E33D-43E6-8B0E-9C51E822C5CAQ34785366-4F87918C-C96B-49CA-821B-5D62C1195621Q35054349-73ED0CEE-D922-48BE-B008-AEC4CE040E9BQ35105463-1ACD01F8-E06D-4989-8BB4-7485FCC52B17Q35559555-C0794EFF-83DE-44EF-A2BE-CA452C9801F0Q35571925-3AC0406E-E94F-406C-B1DE-7BCA6BF50FA6Q35661304-472CDB04-9D88-4042-A27B-F7A2DAD41E40Q35939962-59DA1C00-5E1C-4A1C-AA18-8F21A8029FD4Q35942988-03D2DD84-FFC6-492F-8C3F-DEFEBA26D112Q35944586-B8C1D6EB-F4FF-4AE6-857A-B4AED51B5DBFQ36121450-3CED415D-5374-484B-AFB8-F027242A172CQ36161043-1B97118B-6F0E-48B6-8983-AE630D701236Q36205742-517AD6A3-3E7A-4152-B3DE-4C3F90D2D42DQ36358276-7947D361-A68C-4F13-8349-6AA03C3AF7D5Q36440502-4F5590EF-D656-42EA-81FB-963AE2784944Q36589458-79D4585C-6CBE-4C65-AC28-65B4C79C2AD1Q36841455-31EDCD5C-207A-4B39-9457-5AD34A427399Q36863098-B74EA9F4-770A-4ED4-9C44-32950A1BCAABQ36897429-0C940F62-598A-48D0-AA3A-9774960962D4Q36897967-A247AC83-F8BE-4A86-AB4A-8385AAA4EC90Q37011005-44A37FBE-2012-46F8-A163-9784D94AA524Q37044741-978E4782-CCF7-4155-A73B-31598AD18A3C
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Loss of vaccine-induced immunity to varicella over time
@ast
Loss of vaccine-induced immunity to varicella over time
@en
Loss of vaccine-induced immunity to varicella over time
@nl
type
label
Loss of vaccine-induced immunity to varicella over time
@ast
Loss of vaccine-induced immunity to varicella over time
@en
Loss of vaccine-induced immunity to varicella over time
@nl
prefLabel
Loss of vaccine-induced immunity to varicella over time
@ast
Loss of vaccine-induced immunity to varicella over time
@en
Loss of vaccine-induced immunity to varicella over time
@nl
P2093
P3181
P356
P1476
Loss of vaccine-induced immunity to varicella over time
@en
P2093
Dalya Guris
Jane F Seward
John X Zhang
Laurene Mascola
Paul Gargiullo
Rachel Civen
Sandra S Chaves
P304
P3181
P356
10.1056/NEJMOA064040
P407
P577
2007-03-15T00:00:00Z